Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

0
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Impact Index Per Article
Citation(s) in RCA

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Category

Show more Refine

For: Li Y, Liang X, Li H, Yang T, Guo S, Chen X. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Front Pharmacol 2022;13:906956. [PMID: 35928269 PMCID: PMC9343987 DOI: 10.3389/fphar.2022.906956] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 06/20/2022] [Indexed: 11/27/2022] Open

For:	Li Y, Liang X, Li H, Yang T, Guo S, Chen X. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Front Pharmacol 2022;13:906956. [PMID: 35928269 PMCID: PMC9343987 DOI: 10.3389/fphar.2022.906956] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Accepted: 06/20/2022] [Indexed: 11/27/2022] Open

No articles found.

(The first 100,000 artilces are displayed in RCA.)